Cost-effectiveness of routine measuring of serum drug concentrations and anti-drug antibodies in treatment of rheumatoid arthritis patients with TNF-α blockers

Authors: Laine J, Jokiranta TS, Eklund KK, Väkeväinen M, Puolakka K

Source: Biologics: Targets & Therapy, Vol 2016, Iss Issue 1, Pp 67-73 (2016)

Subject Terms: TNF blockers, anti-drug antibodies, drug concentration, Medicine (General), R5-920

File Description: electronic resource

Relation: https://www.dovepress.com/cost-effectiveness-of-routine-measuring-of-serum-drug-concentrations-a-peer-reviewed-article-BTT; https://doaj.org/toc/1177-5491

Access URL: https://doaj.org/article/0445bfa0021849d5b207becc33be2a18

The validity of rheumatoid arthritis diagnoses in Finnish biobanks

Authors: Paltta, J, Heikkilä, H-K, Pirilä, L, Eklund, KK, Huhtakangas, J, Isomäki, P, Kaipiainen-Seppänen, O, Kristiansson, K, Havulinna, AS, Sokka-Isler, T, Palomäki, A

Source: Scandinavian journal of rheumatology. 52(1):1-9

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100182183999.0x000001&indx=1&recIds=ETOCvdc_100182183999.0x000001

Induction of remission in female rheumatoid arthritis patients is associated with stabilization of myocardial abnormalities: a prospective cardiac magnetic resonance follow-up study

Authors: Koivuniemi, R, Kuuliala, A, Kivistö, S, Holmström, M, Hämäläinen, M, Moilanen, E, Rajamäki, K, Kautiainen, H, Eklund, KK, Leirisalo-Repo, M

Source: Scandinavian journal of rheumatology. 50(2):104-112

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100124329888.0x000001&indx=1&recIds=ETOCvdc_100124329888.0x000001

Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial

Authors: Kuusalo, L, Puolakka, K, Kautiainen, H, Blåfield, H, Eklund, KK, Ilva, K, Kaipiainen-Seppänen, O, Karjalainen, A, Korpela, M, Valleala, H, Leirisalo-Repo, M, Rantalaiho, V

Source: Scandinavian journal of rheumatology. 44(6):449-455

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100048284280.0x000001&indx=1&recIds=ETOCvdc_100048284280.0x000001

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice.

Authors: Shiota, N, Kovanen, PT, Eklund, KK, Shibata, N, Shimoura, K, Niibayashi, T, Shimbori, C, Okunishi, H, Kovanen, P T, Eklund, K K

Source: British Journal of Pharmacology; Feb2010, Vol. 159 Issue 3, p626-635, 10p

Subject Terms: ANTIALLERGIC agents, COLLAGEN diseases, BONE diseases, LABORATORY mice, INFLAMMATION treatment, TREATMENT of arthritis, MAST cells, OSTEOCLASTS, TUMOR necrosis factors

This result is not displayed to guests.
Login for full access.

Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis.

Authors: Eklund KK, Lindstedt K, Sandler C, Kovanen PT, Laasonen L, Juurikivi A, Wolff H, Mykkänen M, Joensuu H

Source: JRC: Journal of Clinical Rheumatology; 2008 Oct, Vol. 14 Issue 5, p294-296, 3p

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.